Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. Nykode Therapeutics AS
  6. News
  7. Summary
    VACC   NO0010714785

NYKODE THERAPEUTICS AS

(VACC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nykode, Regeneron to Team Up On Cancer, Infectious Disease Vaccines

11/23/2021 | 01:13am EST


ę MT Newswires 2021
All news about NYKODE THERAPEUTICS AS
2021Nykode Therapeutics announces first subject dosed with its T cell focused next-generati..
AQ
2021Nykode Therapeutics AS Announces First Subject Dosed with Its T Cell Focused Next-Gener..
CI
2021Minutes of Extraordinary General Meeting
AQ
2021Nykode Therapeutics AS - Mandatory notification of purchase by related party to primary..
AQ
2021Share capital increase from exercise of warrants
AQ
2021Nykode Therapeutics Names New Chair
MT
2021Nykode Therapeutics AS - New name registered
AQ
2021Vaccibody AS*) - Notice of Extraordinary General Meeting
AQ
2021New chairman at Nykode Therapeutics as the Company enters a new stage of internationali..
AQ
2021Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based C..
CI
More news
Financials
Sales 2021 361 M 40,5 M 40,5 M
Net income 2021 4,73 M 0,53 M 0,53 M
Net cash 2021 1 833 M 206 M 206 M
P/E ratio 2021 11 200x
Yield 2021 -
Capitalization 16 219 M 1 810 M 1 819 M
EV / Sales 2021 39,9x
EV / Sales 2022 148x
Nbr of Employees 87
Free-Float -
Chart NYKODE THERAPEUTICS AS
Duration : Period :
Nykode Therapeutics AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NYKODE THERAPEUTICS AS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 56,00 NOK
Average target price 102,00 NOK
Spread / Average Target 82,1%
EPS Revisions
Managers and Directors
Michael Thyrring Engsig Chief Executive Officer
Harald Gurvin Chief Financial Officer
Alf Gunnar Martin Nicklasson Chairman
Mona Welschof Chief Clinical Officer
Mette Husbyn Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
NYKODE THERAPEUTICS AS-30.61%1 810
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796